⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3983446 | 1.00 | — | — | |
| SCHEMBL15319162 | 1.00 | — | — | |
| SCHEMBL3988878 | 0.80 | — | — | |
| SCHEMBL27372969 | 0.77 | — | — | |
| SCHEMBL19337929 | 0.76 | — | — | |
| SCHEMBL18559569 | 0.76 | — | — | |
| SCHEMBL14169405 | 0.75 | ALDH1A1 (0.30) | — | |
| SCHEMBL512751 | 0.74 | — | — | |
| SCHEMBL9985157 | 0.74 | — | — | |
| SCHEMBL1287832 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080588-A1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (US) | 2015-03-19 | — | — | US | claimed |
| EP-2834233-A1 | NEW ALPHA2 ADRENOCEPTOR AGONISTS | Orion Corporation (FI) | 2015-02-11 | — | — | EP | claimed |
| EP-2834234-A1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2015-02-11 | — | — | EP | claimed |
| US-20140018356-A1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-16 | — | — | US | claimed |
| WO-2013150173-A1 | NEW ALPHA2 ADRENOCEPTOR AGONISTS | ORION CORPORATION (FI) | 2013-10-10 | — | — | WO | claimed |
| WO-2013152269-A1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-10 | — | — | WO | claimed |
| EP-4482527-B1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20250154288-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-05-15 | — | — | US | disclosed |
| EP-4482527-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-01-01 | — | — | EP | disclosed |
| WO-2023161874-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023161874-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-08-31 | — | — | WO | disclosed |
| EP-2834234-B1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| EP-2834234-B1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| US-8822460-B2 | Fused cyclopentyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-02 | — | — | US | disclosed |
| US-8822460-B2 | Fused cyclopentyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-02 | — | — | US | disclosed |
| US-8822460-B2 | Fused cyclopentyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-02 | — | — | US | disclosed |
| US-20140018356-A1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-16 | — | — | US | disclosed |
| US-20140018356-A1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-16 | — | — | US | disclosed |
| US-20140018356-A1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-16 | — | — | US | disclosed |
| WO-2013152269-A1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-10 | — | — | WO | disclosed |